The effect of SARS-CoV-2 mRNA vaccination on AMH concentrations in infertile women

Reprod Biomed Online. 2022 Oct;45(4):779-784. doi: 10.1016/j.rbmo.2022.06.015. Epub 2022 Jun 22.

Abstract

Research question: Does SARS-CoV-2 mRNA vaccination affect the ovarian reserve of infertile women undergoing IVF?

Design: This was a prospective observational study at a single university-affiliated IVF unit that included infertile women aged 18-44 years who were undergoing IVF/intracytoplasmic sperm injection between November 2020 and September 2021, had received two doses of SARS-CoV-2 mRNA vaccination and had undergone measurement of baseline anti-Müllerian hormone (AMH) concentration within the 12 months preceding their recruitment. AMH concentrations before and after vaccination were evaluated and compared.

Results: Overall, 31 women were included in the study. The median AMH concentrations before and after COVID-19 vaccine were comparable (1.7 versus 1.6 g/ml, respectively, P = 0.96). No correlation was found between the participant's anti-COVID-19 antibody titre and the change in AMH concentration.

Conclusions: SARS-CoV-2 mRNA vaccination does not adversely affect ovarian reserve, as shown by comparing serum AMH concentrations before and after vaccination. These findings may serve as a counselling tool for clinicians to reassure women undergoing fertility treatment that SARS-CoV-2 mRNA vaccination is safe.

Keywords: Anti-Müllerian hormone; COVID-19; Fertility; Ovarian reserve; SARS-CoV-2 mRNA vaccine.

Publication types

  • Observational Study

MeSH terms

  • Anti-Mullerian Hormone
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Female
  • Humans
  • Infertility, Female* / therapy
  • Ovarian Reserve*
  • RNA, Messenger
  • SARS-CoV-2
  • Vaccination

Substances

  • COVID-19 Vaccines
  • RNA, Messenger
  • Anti-Mullerian Hormone